Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prelude Therapeutics ( (PRLD) ) has provided an update.
On April 15, 2026, Prelude Therapeutics announced that veteran oncologist Charles Morris, M.D., will join the company as Executive Vice President and Chief Medical Officer effective April 20, 2026, bringing more than 30 years of oncology drug development experience and a track record across multiple successful cancer therapies. His appointment includes a $535,000 base salary, performance-based bonus, significant stock option grant and change-in-control protections, underscoring Prelude’s efforts to bolster leadership as its lead oncology programs move toward clinical development in 2026 and potentially strengthening its execution and credibility with investors and partners.
The most recent analyst rating on (PRLD) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses, negative free cash flow, and equity erosion) and a loss-making valuation profile (negative P/E). Offsetting factors include strong technical momentum and constructive corporate catalysts (IND clearance and program progress), though the ATM facility adds dilution risk.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative cancer medicines for areas of high unmet need. Its pipeline includes highly selective KAT6A degraders and JAK2V617F mutant-selective inhibitors, as well as next-generation degrader antibody conjugates with novel payloads, targeting myeloproliferative neoplasms and ER+ breast cancer.
Average Trading Volume: 308,454
Technical Sentiment Signal: Buy
Current Market Cap: $275.3M
For a thorough assessment of PRLD stock, go to TipRanks’ Stock Analysis page.